Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Anti-PD-1
100%
Deficient Mismatch Repair (dMMR)
100%
Mismatch Repair
100%
DNA Mismatch Repair
100%
Confidence Interval
44%
Microsatellite Instability-high (MSI-H)
44%
Progression-free Survival
33%
Reimbursement
22%
Immunohistochemistry
22%
MMR Genes
22%
Multicenter Retrospective Study
11%
Monotherapy
11%
Loss Function
11%
Genetic Modification
11%
Immune Checkpoint Inhibitors
11%
Next-generation Sequencing
11%
Objective Response Rate
11%
Prostate-specific Antigen
11%
Polymerase Chain Reaction Analysis
11%
Median Overall Survival
11%
Protein Loss
11%
Health Authorities
11%
Response Evaluation Criteria in Solid Tumors (RECIST)
11%
Median Progression-free Survival
11%
Mismatch Repair Genes
11%
MMR Proteins
11%
Anti-PD-1 Therapy
11%
Medicine and Dentistry
Castration Resistant Prostate Cancer
100%
DNA Mismatch Repair
100%
Immunotherapy
100%
Progression Free Survival
66%
Immunohistochemistry
33%
Monotherapy
16%
Immune Checkpoint Inhibitor
16%
Retrospective Study
16%
Reaction Analysis
16%
Overall Survival
16%
Survival Rate
16%
Prostate Specific Antigen
16%
Cancer Staging
16%
Protein Depletion
16%
Next Generation Sequencing
16%
Gene Repair
16%
Microsatellite Instability
16%
Polymerase Chain Reaction
16%
Biochemistry, Genetics and Molecular Biology
DNA Mismatch Repair
100%
Progression Free Survival
100%
Retrospective Study
25%
Next Generation Sequencing
25%
Gene Repair
25%
Microsatellite Instability
25%
Overall Survival
25%
Survival Rate
25%
Prostate-Specific Antigen
25%
Cancer Staging
25%
Genomics
25%
Polymerase Chain Reaction
25%
Immune Checkpoint Inhibitor
25%